Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

It’s time to update your counseling on the injectable contraceptive depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer; New York City). The Food and Drug Administration (FDA) has added a “black box” warning to the drug’s labeling to highlight that prolonged use may result in the loss of bone mineral density (BMD).

Be prepared to counsel on use of DMPA and bone health issues